{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:05:37Z","timestamp":1789826737467,"version":"4.0.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Womens Ment Health"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The use of antipsychotics during pregnancy has increased over the past two decades, primarily driven by an increase in the use of second-generation antipsychotic drugs. However, knowledge regarding the reproductive safety of antipsychotic drugs remains limited. This systematic review and meta-analysis investigated the associations between in utero antipsychotic drug exposure and congenital malformations and other neonatal outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of MEDLINE, Embase, and PsycInfo was conducted from database inception to February 2024 for cohort and case-control (English language) studies that examined maternal antipsychotic exposure and reported risk estimates for one or more of the following outcomes: congenital malformation, preterm birth, low birth weight, stillbirth, or neonatal intensive care unit admission. Study quality was assessed using the Newcastle-Ottawa Scale, and reporting was guided by the PRISMA statement and MOOSE guidelines. Pooled estimates were calculated using a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twelve studies (comprising over 10\u00a0million pregnancies across 12 countries) met the inclusion criteria. A pooled meta-analysis of eight studies indicated borderline evidence of an association between the risk of congenital malformations and in utero antipsychotic drug exposure, with moderate heterogeneity (odds ratio [OR] 1.27; 95% confidence interval [CI] 0.996\u20131.624,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0535; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200953%). No association was observed when limited to second-generation antipsychotics (OR 1.16; 95% CI 0.78\u20131.72,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.47). Regarding the outcome of preterm birth, antipsychotic exposure was associated with an increase in risk (OR 1.35; 95% CI 1.13\u20131.62,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), though there was moderate to high heterogeneity (I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200970%). There was insufficient data to perform a meta-analysis for the other outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Meta-analyses did not indicate strong evidence that in utero antipsychotic exposure is a major teratogen; and although an association was observed between maternal antipsychotic use and preterm birth, there was significant heterogeneity across studies. The decision to continue antipsychotic use during pregnancy involves a complex balancing of risks and benefits for women and their healthcare professionals. Any potential risks to the developing foetus must be weighed against the risks of discontinuing treatment, including the possibility of relapse in women with severe mental illness, which can have serious consequences for a woman and her infant. Finally, there is a need for further robustly designed studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00737-025-01651-5","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:15:00Z","timestamp":1767845700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antipsychotic drug use during pregnancy and neonatal outcomes: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"29","author":[{"given":"Dervla","family":"Quinn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciaran","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"1651_CR11","unstructured":"\u2018Covidence systematic review software\u2019 (2024) Veritas Health Innovation, Melbourne, Australia"},{"issue":"5","key":"1651_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1192\/bjp.bp.112.117556","volume":"202","author":"KM Abel","year":"2013","unstructured":"Abel KM (2013) Fetal antipsychotic exposure in a changing landscape: seeing the future. Br J Psychiatry 202(5):321\u2013323. https:\/\/doi.org\/10.1192\/bjp.bp.112.117556","journal-title":"Br J Psychiatry"},{"key":"1651_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.schres.2019.11.019","volume":"215","author":"KN Anderson","year":"2020","unstructured":"Anderson KN et al (2020) Atypical antipsychotic use during pregnancy and birth defect risk: National Birth Defects Prevention Study, 1997\u20132011. Schizophr Res 215:81\u201388. https:\/\/doi.org\/10.1016\/j.schres.2019.11.019","journal-title":"Schizophr Res"},{"issue":"5","key":"1651_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamaneurol.2024.0258","volume":"81","author":"D Battino","year":"2024","unstructured":"Battino D et al (2024) Risk of major congenital malformations and exposure to antiseizure medication monotherapy. JAMA Neurol 81(5):481. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0258","journal-title":"JAMA Neurol"},{"issue":"4","key":"1651_CR4","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/pds.3749","volume":"24","author":"F Bellet","year":"2015","unstructured":"Bellet F et al (2015) Exposure to aripiprazole during embryogenesis: A prospective multicenter cohort study. Pharmacoepidemiol Drug Saf 24(4):368\u2013380. https:\/\/doi.org\/10.1002\/pds.3749","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"1651_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/archgenpsychiatry.2011.1870","volume":"69","author":"R Bod\u00e9n","year":"2012","unstructured":"Bod\u00e9n R et al (2012) Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry 69(7):715\u201321. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.1870","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"1651_CR6","doi-asserted-by":"publisher","first-page":"06","DOI":"10.35946\/ARCR.V40.2.06","volume":"40","author":"G Chang","year":"2020","unstructured":"Chang G (2020) Maternal substance use: consequences, identification, and interventions. Alcohol Res Curr Rev 40(2):06. https:\/\/doi.org\/10.35946\/ARCR.V40.2.06","journal-title":"Alcohol Res Curr Rev"},{"issue":"3","key":"1651_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1176\/appi.ajp.2015.15040506","volume":"173","author":"LS Cohen","year":"2016","unstructured":"Cohen LS et al (2016) Reproductive safety of second-generation antipsychotics: Current data from the Massachusetts general hospital national pregnancy registry for atypical antipsychotics. Am J Psychiatry 173(3):263\u2013270. https:\/\/doi.org\/10.1176\/appi.ajp.2015.15040506","journal-title":"Am J Psychiatry"},{"issue":"12","key":"1651_CR8","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1176\/appi.ajp.2018.18010098","volume":"175","author":"LS Cohen","year":"2018","unstructured":"Cohen LS et al (2018) Risk of major malformations in infants following first-trimester exposure to quetiapine. Am J Psychiatry 175(12):1225\u20131231. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18010098","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1651_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1089\/jwh.2022.0310","volume":"32","author":"LS Cohen","year":"2023","unstructured":"Cohen LS et al (2023) Reproductive Safety of Lurasidone and Quetiapine: Update from the National Pregnancy Registry for Psychiatric Medications. J of Women\u2019s Health 32(4):452\u2013462. https:\/\/doi.org\/10.1089\/jwh.2022.0310","journal-title":"J of Women\u2019s Health"},{"issue":"5","key":"1651_CR10","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1097\/AOG.0000000000000759","volume":"125","author":"CG Coughlin","year":"2015","unstructured":"Coughlin CG et al (2015) Obstetric and Neonatal Outcomes After Antipsychotic Medication Exposure in Pregnancy. Obstet Gynecol 125(5):1224\u20131235. https:\/\/doi.org\/10.1097\/AOG.0000000000000759","journal-title":"Obstet Gynecol"},{"issue":"3","key":"1651_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4088\/jcp.v66n0307","volume":"66","author":"O Diav-Citrin","year":"2005","unstructured":"Diav-Citrin O et al (2005) Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 66(3):317\u201322. https:\/\/doi.org\/10.4088\/jcp.v66n0307","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1651_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00228-019-02769-z","volume":"76","author":"M Ellfolk","year":"2020","unstructured":"Ellfolk M et al (2020) Second-generation antipsychotics and pregnancy complications. Eur J Clin Pharmacol 76(1):107\u2013115. https:\/\/doi.org\/10.1007\/s00228-019-02769-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"1651_CR14","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00228-021-03169-y","volume":"77","author":"M Ellfolk","year":"2021","unstructured":"Ellfolk M et al (2021) Second-generation antipsychotic use during pregnancy and risk of congenital malformations. Eur J Clin Pharmacol 77(11):1737\u20131745. https:\/\/doi.org\/10.1007\/s00228-021-03169-y","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"1651_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277623","volume":"17","author":"A Fisher","year":"2022","unstructured":"Fisher A et al (2022) Patterns of antiemetic medication use during pregnancy: A multi-country retrospective cohort study. PLOS ONE 17(12):e0277623. https:\/\/doi.org\/10.1371\/journal.pone.0277623","journal-title":"PLOS ONE"},{"issue":"5","key":"1651_CR16","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/ajo.12621","volume":"57","author":"J Frayne","year":"2017","unstructured":"Frayne J et al (2017) The effects of gestational use of antidepressants and antipsychotics on neonatal outcomes for women with severe mental illness. Aust N Zeal J Obstet and Gynaecol 57(5):526\u2013532. https:\/\/doi.org\/10.1111\/ajo.12621","journal-title":"Aust N Zeal J Obstet and Gynaecol"},{"issue":"4","key":"1651_CR17","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/S00737-021-01115-6\/TABLES\/4","volume":"24","author":"MP Freeman","year":"2021","unstructured":"Freeman MP et al (2021) Reproductive safety of aripiprazole: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Arch Womens Ment Health 24(4):659\u2013667. https:\/\/doi.org\/10.1007\/S00737-021-01115-6\/TABLES\/4","journal-title":"Arch Womens Ment Health"},{"issue":"4","key":"1651_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/JCP.0b013e318295fe12","volume":"33","author":"F Habermann","year":"2013","unstructured":"Habermann F et al (2013) Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol 33(4):453\u2013462. https:\/\/doi.org\/10.1097\/JCP.0b013e318295fe12","journal-title":"J Clin Psychopharmacol"},{"key":"1651_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061328","author":"E Heinonen","year":"2022","unstructured":"Heinonen E (2022) Neonatal morbidity after fetal exposure to antipsychotics: a national register-based study. BMJ Open 12(6):e061328. https:\/\/doi.org\/10.1136\/bmjopen-2022-061328","journal-title":"BMJ Open"},{"issue":"5","key":"1651_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/S41372-019-0346-5","volume":"39","author":"H Heun-Johnson","year":"2019","unstructured":"Heun-Johnson H et al (2019) Association between maternal serious mental illness and adverse birth outcomes. J Perinatol 39(5):737. https:\/\/doi.org\/10.1038\/S41372-019-0346-5","journal-title":"J Perinatol"},{"issue":"3","key":"1651_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/wps.20769","volume":"19","author":"LM Howard","year":"2020","unstructured":"Howard LM, Khalifeh H (2020) Perinatal mental health: a review of progress and challenges. World Psychiatry 19(3):313\u2013327. https:\/\/doi.org\/10.1002\/wps.20769","journal-title":"World Psychiatry"},{"issue":"9","key":"1651_CR22","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1001\/jamapsychiatry.2016.1520","volume":"73","author":"KF Huybrechts","year":"2016","unstructured":"Huybrechts KF et al (2016) Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatr 73(9):938\u2013946. https:\/\/doi.org\/10.1001\/jamapsychiatry.2016.1520","journal-title":"JAMA Psychiatr"},{"issue":"2","key":"1651_CR23","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jamapsychiatry.2022.4109","volume":"80","author":"KF Huybrechts","year":"2023","unstructured":"Huybrechts KF et al (2023) Association of in utero antipsychotic medication exposure with risk of congenital malformations in Nordic countries and the US. JAMA Psychiatr 80(2):156. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.4109","journal-title":"JAMA Psychiatr"},{"issue":"1","key":"1651_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1176\/APPI.AJP.162.1.79","volume":"162","author":"AV Jablensky","year":"2005","unstructured":"Jablensky AV et al (2005) Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry 162(1):79\u201391. https:\/\/doi.org\/10.1176\/APPI.AJP.162.1.79","journal-title":"Am J Psychiatry"},{"key":"1651_CR25","doi-asserted-by":"publisher","unstructured":"Joseph-Delaffon K et al (2024) Neonatal outcomes after in utero exposure to antipsychotics: a systematic review and meta-analysis.\u00a0Eur J Epidemiol\u00a039(10):1073\u20131096. Available at: https:\/\/doi.org\/10.1007\/s10654-024-01156-y","DOI":"10.1007\/s10654-024-01156-y"},{"key":"1651_CR26","doi-asserted-by":"publisher","unstructured":"Kananen A (2023) Quetiapine and other antipsychotic medications during pregnancy: a 15-year follow-up of a university hospital birth register. Nord J Psychiatry 77(7):651\u2013660. https:\/\/doi.org\/10.1080\/08039488.2023.2205852","DOI":"10.1080\/08039488.2023.2205852"},{"issue":"1","key":"1651_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.schres.2009.10.011","volume":"116","author":"HC Lin","year":"2010","unstructured":"Lin HC et al (2010) Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? Schizophr Res 116(1):55\u201360. https:\/\/doi.org\/10.1016\/j.schres.2009.10.011","journal-title":"Schizophr Res"},{"issue":"11","key":"1651_CR28","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.mayocp.2022.04.006","volume":"97","author":"H-Y Lin","year":"2022","unstructured":"Lin H-Y et al (2022) Antipsychotic use in early pregnancy and the risk of maternal and neonatal complications. Mayo Clin Proc 97(11):2086\u20132096. https:\/\/doi.org\/10.1016\/j.mayocp.2022.04.006","journal-title":"Mayo Clin Proc"},{"key":"1651_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2023.100950","author":"X Liu","year":"2023","unstructured":"Liu X (2023) Maternal antipsychotic use during pregnancy and congenital malformations. Am J Obstet Gynecol MFM 5(6):100950. https:\/\/doi.org\/10.1016\/j.ajogmf.2023.100950","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"2","key":"1651_CR30","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1177\/1753495X17750299","volume":"11","author":"K-A Louw","year":"2018","unstructured":"Louw K-A (2018) Substance use in pregnancy: the medical challenge. Obstet Med 11(2):54\u201366. https:\/\/doi.org\/10.1177\/1753495X17750299","journal-title":"Obstet Med"},{"issue":"4","key":"1651_CR31","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4088\/jcp.v66n0406","volume":"66","author":"K McKenna","year":"2005","unstructured":"McKenna K et al (2005) Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 66(4):444\u20139. https:\/\/doi.org\/10.4088\/jcp.v66n0406","journal-title":"J Clin Psychiatry"},{"key":"1651_CR32","unstructured":"Medicines and Healthcare products Regulatory Agency (2011) Antipsychotics: risk of extrapyramidal effects or withdrawal symptoms in newborns, Drug Safety Update. Available at: https:\/\/www.gov.uk\/drug-safety-update\/antipsychotics-risk-of-extrapyramidal-effects-or-withdrawal-symptoms-in-newborns (Accessed: 6 November 2024)"},{"issue":"2","key":"1651_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/ebmental-2019-300129","volume":"23","author":"S Metelli","year":"2020","unstructured":"Metelli S, Chaimani A (2020) Challenges in meta-analyses with observational studies. Evid Based Ment Health 23(2):83\u201387. https:\/\/doi.org\/10.1136\/ebmental-2019-300129","journal-title":"Evid Based Ment Health"},{"issue":"1","key":"1651_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-019-2572-4","volume":"19","author":"D Mongan","year":"2019","unstructured":"Mongan D et al (2019) Prevalence of self-reported mental disorders in pregnancy and associations with adverse neonatal outcomes: a population-based cross-sectional study. BMC Pregnancy Childbirth 19(1):412. https:\/\/doi.org\/10.1186\/s12884-019-2572-4","journal-title":"BMC Pregnancy Childbirth"},{"issue":"8","key":"1651_CR35","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1176\/APPI.AJP.2007.06111886","volume":"164","author":"DJ Newport","year":"2007","unstructured":"Newport DJ et al (2007) Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 164(8):1214\u20131220. https:\/\/doi.org\/10.1176\/APPI.AJP.2007.06111886","journal-title":"Am J Psychiatry"},{"key":"1651_CR36","doi-asserted-by":"publisher","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ, 372. Available at: https:\/\/doi.org\/10.1136\/BMJ.N71","DOI":"10.1136\/BMJ.N71"},{"issue":"11","key":"1651_CR37","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1176\/appi.ps.201600408","volume":"68","author":"Y Park","year":"2017","unstructured":"Park Y et al (2017) Antipsychotic medication use among publicly insured pregnant women in the United States. Psychiatr Serv 68(11):1112\u20131119. https:\/\/doi.org\/10.1176\/appi.ps.201600408","journal-title":"Psychiatr Serv"},{"issue":"2\u20133","key":"1651_CR38","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.schres.2016.07.023","volume":"176","author":"I Petersen","year":"2016","unstructured":"Petersen I et al (2016) Risks associated with antipsychotic treatment in pregnancy: comparative cohort studies based on electronic health records. Schizophr Res 176(2\u20133):349\u2013356. https:\/\/doi.org\/10.1016\/j.schres.2016.07.023","journal-title":"Schizophr Res"},{"issue":"3","key":"1651_CR39","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/JCP.0b013e318172b8d5","volume":"28","author":"M Reis","year":"2008","unstructured":"Reis M, K\u00e4ll\u00e9n B (2008) Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 28(3):279\u2013288. https:\/\/doi.org\/10.1097\/JCP.0b013e318172b8d5","journal-title":"J Clin Psychopharmacol"},{"key":"1651_CR40","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.schres.2020.03.048","volume":"220","author":"J Reutfors","year":"2020","unstructured":"Reutfors J et al (2020) Antipsychotic drug use in pregnancy: a multinational study from ten countries. Schizophr Res 220:106\u2013115. https:\/\/doi.org\/10.1016\/j.schres.2020.03.048","journal-title":"Schizophr Res"},{"issue":"1","key":"1651_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/tera.1420150108","volume":"15","author":"C Rumeau-Rouquette","year":"1977","unstructured":"Rumeau-Rouquette C, Goujard J, Huel G (1977) Possible teratogenic effect of phenothiazines in human beings. Teratology 15(1):57\u201364. https:\/\/doi.org\/10.1002\/tera.1420150108","journal-title":"Teratology"},{"key":"1651_CR42","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1136\/bmjopen-2013","volume":"3","author":"A Sadowski","year":"2013","unstructured":"Sadowski A et al (2013) Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open 3:3062. https:\/\/doi.org\/10.1136\/bmjopen-2013","journal-title":"BMJ Open"},{"issue":"5","key":"1651_CR43","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/0002-9378(77)90029-1","volume":"128","author":"D Slone","year":"1977","unstructured":"Slone D et al (1977) Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 128(5):486\u2013488. https:\/\/doi.org\/10.1016\/0002-9378(77)90029-1","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"1651_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0132280","volume":"10","author":"MJ S\u00f8rensen","year":"2015","unstructured":"S\u00f8rensen MJ et al (2015) Risk of fetal death after treatment with antipsychotic medications during pregnancy. PLoS One 10(7):e0132280. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0132280","journal-title":"PLoS One"},{"key":"1651_CR45","volume-title":"Stata statistical software: release 18","author":"StataCorp","year":"2023","unstructured":"StataCorp (2023) Stata statistical software: release 18. StataCorp LLC, College Station, TX"},{"issue":"11","key":"1651_CR46","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ogrm.2020.09.002","volume":"30","author":"S Steele","year":"2020","unstructured":"Steele S, Osorio R, Page LM (2020) Substance misuse in pregnancy. Obstetrics, Gynaecology & Reproductive Medicine 30(11):347\u2013355. https:\/\/doi.org\/10.1016\/j.ogrm.2020.09.002","journal-title":"Obstetrics, Gynaecology & Reproductive Medicine"},{"issue":"15","key":"1651_CR47","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/JAMA.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008\u20132012. https:\/\/doi.org\/10.1001\/JAMA.283.15.2008","journal-title":"JAMA"},{"issue":"7","key":"1651_CR48","doi-asserted-by":"publisher","first-page":"967","DOI":"10.4088\/JCP.14m09070","volume":"76","author":"AL Sutter-Dallay","year":"2015","unstructured":"Sutter-Dallay AL et al (2015) Impact of prenatal exposure to psychotropic drugs on neonatal outcome in infants of mothers with serious psychiatric illnesses. J Clin Psychiatry 76(7):967\u2013973. https:\/\/doi.org\/10.4088\/JCP.14m09070","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1651_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-042753","volume":"11","author":"K Thomson","year":"2021","unstructured":"Thomson K et al (2021) Socioeconomic inequalities and adverse pregnancy outcomes in the UK and Republic of Ireland: a systematic review and meta-analysis. BMJ Open 11(3):e042753. https:\/\/doi.org\/10.1136\/bmjopen-2020-042753","journal-title":"BMJ Open"},{"issue":"2","key":"1651_CR50","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00737-013-0330-6","volume":"16","author":"S Toh","year":"2013","unstructured":"Toh S et al (2013) Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001\u20132007: a population-based study of 585,615 deliveries. Arch Womens Ment Health 16(2):149\u2013157. https:\/\/doi.org\/10.1007\/s00737-013-0330-6","journal-title":"Arch Womens Ment Health"},{"key":"1651_CR51","doi-asserted-by":"publisher","unstructured":"Vigod SN et al (2015) Antipsychotic drug use in pregnancy: High dimensional, propensity matched, population based cohort study. BMJ (Online), 350:h2298. Available at: https:\/\/doi.org\/10.1136\/bmj.h2298","DOI":"10.1136\/bmj.h2298"},{"issue":"4","key":"1651_CR52","doi-asserted-by":"publisher","first-page":"35609","DOI":"10.4088\/JCP.20M13745","volume":"82","author":"AC Viguera","year":"2021","unstructured":"Viguera AC et al (2021) Reproductive Safety of Second-Generation Antipsychotics: Updated Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. J Clin Psychiatry 82(4):35609. https:\/\/doi.org\/10.4088\/JCP.20M13745","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1651_CR53","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/JCP.0000000000001665","volume":"43","author":"AC Viguera","year":"2023","unstructured":"Viguera AC et al (2023) Risk of Major Malformations Following First-Trimester Exposure to Olanzapine: Preliminary Data from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. J Clin Psychopharmacol 43(2):106\u2013112. https:\/\/doi.org\/10.1097\/JCP.0000000000001665","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"1651_CR55","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1111\/BCP.14839","volume":"87","author":"Z Wang","year":"2021","unstructured":"Wang Z, Brauer R et al (2021) Prenatal exposure to antipsychotic agents and the risk of congenital malformations in children: a systematic review and meta-analysis. Br J Clin Pharmacol 87(11):4101\u20134123. https:\/\/doi.org\/10.1111\/BCP.14839","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"1651_CR54","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jamainternmed.2021.4571","volume":"181","author":"Z Wang","year":"2021","unstructured":"Wang Z, Chan AYL et al (2021) Association Between Prenatal Exposure to Antipsychotics and Attention-Deficit\/Hyperactivity Disorder, Autism Spectrum Disorder, Preterm Birth, and Small for Gestational Age. JAMA Intern Med 181(10):1332. https:\/\/doi.org\/10.1001\/jamainternmed.2021.4571","journal-title":"JAMA Intern Med"},{"key":"1651_CR56","unstructured":"Wells GA et al (no date) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (Accessed: 7 November\u00a02024)"},{"key":"1651_CR57","doi-asserted-by":"publisher","unstructured":"Yakuwa N et al (2022) Pregnancy outcomes with exposure to second-generation antipsychotics during the first trimester. J Clin Psychiatry 83(4):21m14081. https:\/\/doi.org\/10.4088\/JCP.21M14081","DOI":"10.4088\/JCP.21M14081"}],"container-title":["Archives of Women's Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-025-01651-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00737-025-01651-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-025-01651-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:24:05Z","timestamp":1772000645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00737-025-01651-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1651"],"URL":"https:\/\/doi.org\/10.1007\/s00737-025-01651-5","relation":{},"ISSN":["1434-1816","1435-1102"],"issn-type":[{"value":"1434-1816","type":"print"},{"value":"1435-1102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}